Buy this article for $7.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.



August 2004, Volume 34 Number 8 , p 32cc8 - 32cc8




  • Source

    Diuretics, the mainstay of treatment for heart failure, can cause electrolyte abnormalities and worsen renal function. A new study suggests that giving tolvaptan, a vasopressin antagonist, in addition to standard therapy can reduce fluid volume in patients with heart failure without harming electrolyte balance or renal function.

    In the study, 319 patients were randomly assigned to receive 30, 60, or 90 mg/day of oral tolvaptan or placebo in addition to standard therapy, including non-potassium-sparing diuretics. Patients in the study had left ventricular ejection fractions less than 40%, were hospitalized for heart failure, and continued to have signs and symptoms of systemic congestion despite standard therapy.

    After 24 hours of treatment, patients in the tolvaptan groups had reduced body weights compared with patients receiving placebo, but didn't have changes in heart rate or blood pressure and didn't have hypokalemia ...

To continue reading, buy this article for just $7.95.

Have a coupon or promotional code? Enter it here: